Enanta Pharmaceuticals | ENTA - Current Assets


Enanta Pharmaceuticals reported $198.68M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
AbbVie USD 33.53B 4.47B Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
Anika Therapeutics USD 93.56M 9.8M Mar/2026
Arrowhead Research USD 1.84B 665.36M Mar/2026
AstraZeneca USD 29.61B 890M Mar/2026
BioCryst Pharmaceuticals USD 373.62M 30.72M Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Gilead Sciences USD 18.64B 1.25B Mar/2026
GlaxoSmithKline GBP 17.76B 251M Mar/2026
Halozyme Therapeutics USD 1B 177.83M Mar/2026
Heron Therapeutics USD 228.98M 9.08M Mar/2026
Immunic USD 188.76M 165.89M Mar/2026
Incyte USD 5.48B 460.36M Mar/2026
Insmed USD 1.61B 181.04M Mar/2026
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
J&J USD 59.77B 601M Jun/2026
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
Ligand Pharmaceuticals USD 865.42M 33.14M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Neurocrine Biosciences USD 2.44B 86.6M Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Novavax USD 850.82M 127.46M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
PTC Therapeutics USD 2.25B 19.94M Mar/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026